China makes new progress in developing COVID-19 drugs, some in clinical trials

In a boost to its fight against COVID-19, China is accelerating the development of drugs while promoting vaccination.

A combination therapy of monoclonal antibodies BRII-196 and BRII-198jointly developed by Tsinghua University, the Third People's Hospital of Shenzhen and Brii Biosciences has shown promising results for non-hospitalized COVID-19 patients at high risk of clinical progression to severe disease.

"Our body produces a lot of antibodies, but not all of them have antiviral properties. The goal of our research is to select the strongest and best antiviral antibodies to develop drugs for treatment," Professor Zhang Linqi of Tsinghua's School of Medicine told Science and Technology Daily in a recent interview.

Zhang said the team screened the two highly active and complementary antibodies from hundreds isolated from the blood of convalescent COVID-19 patients.

"The BRII-196/BRII-198 medicines have been used in the clinical treatment of over 700 patients in China, and the clinical trials data at home and overseas shows the medicines could reduce severe symptoms and mortality by 78 percent," he said.

Brii Biosciences has submitted an emergency use authorization (EUA) filing of the therapy to the U.S. Food and Drug Administration (FDA) on a rolling basis, and also submitted an interim report of phase III clinical trials overseas to the Center for Drug Evaluation of China's National Medical Products Administration.

DXP-604, a new neutralizing antibody drug, has also been approved at the Beijing Ditan Hospital for compassionate use, an option to treat patients with life-threatening conditions with medical products outside of clinical trials when no other treatments are available.

The drug, developed by a research team from Peking University led by Professor Xie Xiaoliang and Beijing DanXu Pharmaceuticals, can protect against COVID-19 variants with a lower production cost – about one-third of other candidates, Xie told Science and Technology Daily.

According to Xie, the drug is now under phase II clinical trials in China, and they have contacted Sinopharm, the state-owned pharmaceuticals maker, to promote phase II and III clinical trials overseas.

Proxalutamide, an oral androgen receptor antagonist developed by China's Kintor Pharmaceutical Limited, has been granted emergency use authorization in Paraguay.

The company said Proxalutamide is the only small-molecule oral drug that has entered a phase III multi-regional clinical trial (MRCT) for treating hospitalized COVID-19 patients.

More than 100 sites in 14 countries participate in this MRCT clinical trial, which has been greenlighted/approved by authorities in China, the U.S., the Philippines and Brazil, said Tong Youzhi, chairman and chief executive officer of Kintor. "We continue to seek approvals by regulatory agencies in European and Asian countries."

Sinopharmhas also announced the development of two COVID-19 drugs that could reduce the impact of the virus.

Countries around the world are also seeking antiviral drug treatment for COVID-19.

The UKhas become the first country in the world to approve a COVID-19 drug.

Known as molnupiravir, it is jointly developed by Merck & Co Inc. and Ridgeback Biotherapeutics.

It is recommended for use in "people with mild to moderate COVID-19 and at least one risk factor for developing severe illness, such as obesity, older age diabetes, and heart disease," Reuters reported.

Another pharmaceutical giant Pfizer has applied to the U.S. FDA for EUA of its antiviral COVID-19 pill

Paxlovid

, a combination of a new molecule, PF-07321332, and HIV antiviral ritonavir.

It could be available by late this year or early next given the timeline between the application and subsequent authorization.

Source(s):CGTN